Introduction

In January, the Food and Drug Administration granted accelerated approval to Lecanamab for treating Alzheimer's disease. Like some other recent FDA authorizations under the Accelerated Approval Program, this approval generated controversy. Dr. Ross has co-authored a perspective article about shifts in the FDA's use of accelerated approval.